Demodex blepharitis impacts approximately 25 million eye care patients in the U.S. – or 1 out of every 12 adults. XDEMVY is indicated for all adult patients with Demodex blepharitis and is available ...

Dr Shamie shares her optimism in the advancement of Demodex Blepharitis treatment. This is a video synopsis/summary of an Insights involving Neda Shamie, MD. With an FDA-approved treatment now ...

An overview of the current landscape of available treatment options for Demodex blepharitis is analyzed. This is a video synopsis/summary of a discussion involving Elizabeth Yeu, MD. Yeu discusses how ...

Xdemvy is an eye drop prescribed for adults to treat Demodex blepharitis, an eyelid condition caused by mites. The recommended dosage is 1 drop in each eye twice per day for 6 weeks. While some people ...

Please provide your email address to receive an email when new articles are posted on . Demodex blepharitis is so common that it makes up more than two thirds of all blepharitis cases. In fact, nearly ...

Blepharitis, a chronic condition that causes inflammation of the eyelids, affects millions of people across the United States. Despite being common, it is frequently underdiagnosed or mistaken for ...

Blepharitis is a condition that causes inflammation of the eyelid. A person with blepharitis may experience swollen, irritated, and itchy eyelids. A stye is a painful lump that develops on the upper ...

Viatris Inc. (NASDAQ:VTRS) saw its stock drop 3.6% following news that its late-stage trial for MR-139, a potential treatment for blepharitis, did not achieve its primary endpoint. The Phase 3 study, ...